-
 Cell Therapeutics Inc. - CTIC
Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Jan 7, 2009 1:30:00 AM
Email Story Discuss on ZenoBank
View Additional Profiles
SEATTLE, Jan. 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has received notification that the NASDAQ Listing Qualifications Panel has granted CTI's request to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market, which will be effective with the open of trading on Thursday, January 8, 2009. CTI's shares will continue to trade under the ticker symbol CTIC.
CTI's continued listing on The NASDAQ Capital Market is subject to CTI evidencing compliance with all applicable requirements for continued listing on The NASDAQ Capital Market, including the $35 million market value of listed securities requirement or its alternatives, as set forth in NASDAQ Marketplace Rule 4310(c)(3), by February 12, 2009. The Company expects to comply with all applicable requirements for continued listing on The NASDAQ Capital Market by February 12, 2009; however, there can be no assurance that it will be able to do so.
As disclosed on September 6 and October 10, 2008, CTI was previously notified by NASDAQ regarding its non-compliance with the $50 million market value of listed securities requirement for continued listing on The NASDAQ Global Market. In response, CTI appeared before the NASDAQ Listing Qualifications Panel at a hearing at which it requested the transfer of its listing to The NASDAQ Capital Market pursuant to its plan to evidence compliance with the $35 million market value of listed securities requirement for continued listing on that market.
The NASDAQ Capital Market is one of the three market tier designations for NASDAQ-listed stocks and operates in substantially the same manner as The NASDAQ Global Market. Securities listed on The NASDAQ Capital Market must satisfy all applicable qualification requirements for NASDAQ securities, and companies listed on The NASDAQ Capital Market must meet certain financial requirements and adhere to NASDAQ's corporate governance standards.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to achieve compliance with the NASDAQ Capital Market's continued listing requirements by February 12, including the market value of listed securities requirement, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's need to raise additional capital, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation, the potential failure of a product to prove safe and effective for treatment of a specific condition, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling the product(s). You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T : 206.272.4347
F : 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
SOURCE Cell Therapeutics, Inc.
----------------------------------------------
Media
Dan Eramian
+1-206-272-4343
cell
+1-206-854-1200
media@ctiseattle.com
or Investors
Ed Bell
+1-206-272-4345
or Lindsey Jesch Logan
+1-206-272-4347
fax
+1-206-272-4434
invest@ctiseattle.com
all of Cell Therapeutics
Inc.
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimer click here
-
Re: Cell Therapeutics Inc. - CTIC
Is this good or bad news for this stock?
-
Re: Cell Therapeutics Inc. - CTIC
Cell Therapeutics trading halted by two exchanges
Trading in Cell Therapeutics (CTIC) shares was halted on both the Nasdaq and the Boursa Italiana in Milan on Tuesday, and the company did not provide an explanation.
as reported by The Seattle Times Company
http://seattletimes.nwsource.com/htm...peutics11.html
Last edited by DeninK; 02-11-2009 at 04:38 PM.
Denin K
Newbie
GreenTech Follower
-
 Cell Therapeutics to Resume Trading on MTA and NASDAQ
Cell Therapeutics to Resume Trading on MTA and NASDAQ 
Tuesday , February 17, 2009 20:30ET
KNOBIAS: RAiDAR Story
SEATTLE, Feb. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that, following the issuance of a press release in Italy in response to information requested by the Italian securities regulatory authority, CONSOB, regarding CTI's business operations and financial condition, which was also furnished on a Form 8-K in the U.S. on February 17, 2009, the Borsa Italiana has confirmed that it will re-initiate trading in CTI's shares effective with the open of trading in Italy on February 18, 2009. Based on the foregoing and CTI's communications with NASDAQ, CTI also anticipates that NASDAQ will re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ on February 18, 2009.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..
This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that that NASDAQ may not re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ within the anticipated time frame, the Company's current extension of time to comply with the NASDAQ listing requirements may not be extended by the NASDAQ Qualification Panel and the Company may be delisted by NASDAQ; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
SOURCE Cell Therapeutics, Inc.
Contacts:
Media
Dan Eramian
206-272-4343
cell
206-854-1200
media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors, Ed Bell
206-272-4345
Lindsey Jesch
206-272-4347
fax
206-272-4434
invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
all of Cell Therapeutics, Inc.
Public Companies Associated with this story:
CTIC
Knobias Subject Codes Associated with this story:
Market Listings
Content provided by PR Newswire Copyright © 2009
Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com
KNOBIAS: RAiDAR Story
ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.
Last edited by TGK; 02-21-2009 at 05:58 AM.
Reason: update
-
 02/18/2009 (01:30 ET) Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Comple
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
Wednesday, February 18, 2009 01:30ET
KNOBIAS: RAiDAR Story
SEATTLE, Feb. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that updated safety and efficacy data from the phase III trial of pixantrone provides further support for a robust clinical benefit for pixantrone when used as single agent therapy in the treatment of multiple relapsed aggressive non-Hodgkin's lymphoma (NHL). On an intent-to-treat analysis, pixantrone recipients who achieved a complete remission did so during the first 2 cycles of therapy, compared to 4 cycles among standard chemotherapy recipients, (1.9 months vs. 3.6 months, pixantrone vs. standard chemotherapy). The duration of response in the patients was similar in the 37% of pixantrone patients who had either a partial or complete response compared to the 14% of comparator patients with a major response. However, the overall progression free survival (PFS) was significantly longer in the pixantrone arm (4.7 months vs. 2.6 months, hazard ratio = 0.6; p = 0.0074, pixantrone vs. standard chemotherapy). Thirty-two percent (32%) of pixantrone patients received all 6 cycles of therapy, with 84% receiving 5 of 6 cycles of treatment. Pixantrone recipients had a low incidence of severe neutropenia complicated by either fever or documented infections, or severe vomiting or diarrhea. Pixantrone patients also experienced a low incidence of hair loss, a very common side effect of other drugs in this class. Overall, the incidence of serious adverse events was similar between pixantrone and the control arm. The pixantrone patients had a higher incidence of leucopenia and neutropenia and numerically more severe cardiac events (4 vs 2) than in the control arm. Disease progression reported as an adverse event was less frequent in the pixantrone than in the control arm (1.5% vs. 13.4%).
"We were impressed to see that 84% of patients received at least 5 cycles of pixantrone therapy with a median total dose of 1,475 mg, despite having had significant prior therapy with doxorubicin, an agent in a similar class with cumulative cardiotoxicity," noted Jack Singer, M.D., Chief Medical Officer at CTI. "The rapid time-to-response data coupled with the relatively low incidence of traditional anthracycline toxicities and a safety profile that compares favorably to standard chemotherapy, positions pixantrone to live up to the promise of providing patients with relapsed aggressive NHL a meaningful clinical benefit."
CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients.
CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non- Hodgkin's lymphoma ( NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.
The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004, and pixantrone has received fast track designation for this indication.
About Pixantrone
Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza- anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..
Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
SOURCE Cell Therapeutics, Inc.
Contacts:
Media
Dan Eramian
206-272-4343
cell
206-854-1200
media@ctiseattle.com
Investors, Ed Bell
206-282-7100
Lindsey Jesch Logan
206-272-4347
fax
206-272-4434
invest@ctiseattle.com
all of Cell Therapeutics, Inc.
Public Companies Associated with this story:
CTIC
Content provided by PR Newswire Copyright © 2009
Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com
KNOBIAS: RAiDAR Story
ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.
-
 02/17/2009 (20:30 ET) Cell Therapeutics to Resume Trading on MTA and NASDAQ - PR Newswire
Cell Therapeutics to Resume Trading on MTA and NASDAQ
Tuesday , February 17, 2009 20:30ET
KNOBIAS: RAiDAR Story
SEATTLE, Feb. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that, following the issuance of a press release in Italy in response to information requested by the Italian securities regulatory authority, CONSOB, regarding CTI's business operations and financial condition, which was also furnished on a Form 8-K in the U.S. on February 17, 2009, the Borsa Italiana has confirmed that it will re-initiate trading in CTI's shares effective with the open of trading in Italy on February 18, 2009. Based on the foregoing and CTI's communications with NASDAQ, CTI also anticipates that NASDAQ will re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ on February 18, 2009.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..
This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that that NASDAQ may not re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ within the anticipated time frame, the Company's current extension of time to comply with the NASDAQ listing requirements may not be extended by the NASDAQ Qualification Panel and the Company may be delisted by NASDAQ; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
SOURCE Cell Therapeutics, Inc.
Contacts:
Media
Dan Eramian
206-272-4343
cell
206-854-1200
media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors, Ed Bell
206-272-4345
Lindsey Jesch
206-272-4347
fax
206-272-4434
invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
all of Cell Therapeutics, Inc.
Public Companies Associated with this story:
CTIC
Knobias Subject Codes Associated with this story:
Market Listings
Content provided by PR Newswire Copyright © 2009
Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com
KNOBIAS: RAiDAR Story
ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.
-
02/17/2009 (17:30 ET) CTIC: Filed New Form 8-K, Material Event Disclosure - Edgar
02/17/2009 (17:30 ET) CTIC: Filed New Form 8-K, Material Event Disclosure - Edgar
Please click here to read the full 8-K report.
Form 8-K
8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: (Date of earliest event reported): February 17, 2009
CELL THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Form 8-K
-
02/20/2009 (16:05 ET) Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Ve
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Friday , February 20, 2009 16:05ET
KNOBIAS: RAiDAR Story
3 Month Chart
CTIC - SharpCharts from StockCharts.com
CTI to focus on Pixantrone and OPAXIO Approval and Commercialization
SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum established a joint venture in December 2008 to develop and commercialize Zevalin. At that time CTI contributed all of the Zevalin related assets to the joint venture and sold to Spectrum a 50% membership interest in the joint venture for $15 million, plus certain milestone payments.
The Company will focus its resources on the approval of pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ovarian cancer. CTI estimates that as a result of the sale of the Zevalin interest it will reduce expenses by approximately $15 million annually from activities previously associated with Zevalin while providing CTI with non-dilutive source of operating capital.
"CTI continues to believe in the value of Zevalin as a commercially attractive product and effective form of cancer therapy; however, with the impressive clinical trial results for pixantrone and given the company's need for operating capital, we are compelled to exercise our option and focus our resources on pixantrone," noted James Bianco, MD, CEO of CTI. "CTI has been proud to have provided Zevalin to patients since we acquired it in December, 2007 and having the foresight to bring the first line consolidation for indolent NHL data to the FDA for potential label expansion in the front line consolidation setting. With the progress we made in removing many of the barriers that prevent its more widespread use, we are confident Spectrum will be able to ultimately make Zevalin a commercially attractive product."
At the closing of the sale of CTI's 50% membership interest in the joint venture to Spectrum, CTI will receive $6 million, with the remainder of the $18 million to be paid within 90 days following such closing. The closing of the sale option transaction is contingent upon the satisfaction of certain closing conditions, including the delivery of a legal opinion from counsel to CTI, as specified in the operating agreement for the Zevalin joint venture. CTI believes that it will be in a position to promptly satisfy all of the closing conditions.
About Zevalin(R)
Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.
Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.
Patients and healthcare professionals can visit Zevalin - Non-Hodgkin's Lymphoma Therapy with Rituximab for more information.
About Non-Hodgkin's Lymphoma
Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms - aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with NHL in 2008. Additionally, approximately 19,160 are expected to die from this disease in 2008.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential for Zevalin FIT data to be acceptable to the FDA for this expanded indication or any other indication, the determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling Zevalin. There is also a risk that even if label expansion of Zevalin is approved, it may not result in a significant market increase for the drug due to the presence of other treatment options, failure to gain market acceptance and other factors. Additionally, the closing of the sale option and receipt of the purchase price assumes that the company will be able to satisfy all of the closing conditions and that Spectrum fulfills its legal obligations to timely deliver the purchase price. Disposition of our interest in Zevalin may not reduce our expenses to the extent as currently projected. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
SOURCE Cell Therapeutics, Inc.
Contacts:
Media
Dan Eramian
206-272-4343, C
206-854-1200
media@ctiseattle.com
Investors, Ed Bell
206-272-4345
Lindsey Jesch Logan
206-272-4347, F
206-272-4434
invest@ctiseattle.com
all of Cell Therapeutics, Inc.
Public Companies Associated with this story:
CTIC
Knobias Subject Codes Associated with this story:
Divestiture/Asset Disposition Major Agreements Merger/Acquisition
Content provided by PR Newswire Copyright © 2009
Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com
KNOBIAS: RAiDAR Story
3 Month Chart
CTIC - SharpCharts from StockCharts.com
ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.
Last edited by TGK; 02-21-2009 at 06:17 AM.
Reason: update
-
Re: Cell Therapeutics Inc. - CTIC
 Originally Posted by DeninK
02/17/2009 (20:30 ET) Cell Therapeutics to Resume Trading on MTA and NASDAQ - PR Newswire
KNOBIAS: RAiDAR Story
Cell Therapeutics to Resume Trading on MTA and NASDAQ
Tuesday , February 17, 2009 20:30ET
KNOBIAS: RAiDAR Story
SEATTLE, Feb. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that, following the issuance of a press release in Italy in response to information requested by the Italian securities regulatory authority, CONSOB, regarding CTI's business operations and financial condition, which was also furnished on a Form 8-K in the U.S. on February 17, 2009, the Borsa Italiana has confirmed that it will re-initiate trading in CTI's shares effective with the open of trading in Italy on February 18, 2009. Based on the foregoing and CTI's communications with NASDAQ, CTI also anticipates that NASDAQ will re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ on February 18, 2009.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..
This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that that NASDAQ may not re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ within the anticipated time frame, the Company's current extension of time to comply with the NASDAQ listing requirements may not be extended by the NASDAQ Qualification Panel and the Company may be delisted by NASDAQ; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
SOURCE Cell Therapeutics, Inc.
Contacts:
Media
Dan Eramian
206-272-4343
cell
206-854-1200
media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors, Ed Bell
206-272-4345
Lindsey Jesch
206-272-4347
fax
206-272-4434
invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
all of Cell Therapeutics, Inc.
Public Companies Associated with this story:
CTIC
Knobias Subject Codes Associated with this story:
Market Listings
KNOBIAS: RAiDAR Story
-
Cell Therapeutics Inc (nasdaq: CTIC) Stock Symbol:Company Profile:
Cell Therapeutics Inc (nasdaq: CTIC) Stock Symbol:Company Profile:
Quotes and Research
Knobias MEMBERS get: Quotes | Charts | Technical Analysis | Quick Profiles | EDGAR Filings | News & Alerts | TearSheet Profiles | Historical Statistics | Insider Transactions | Institutional Holdings | ...and Much More
Quotes and Research
Last Trade: 0.054 Change: -0.008 ( -12.439 %)
Previous Close: 0.061 Today's Open: 0.062
# of Trades: 2,875 Volume: 3,713,609
Avg. # of Trades: 823 Avg. Daily Volume: 9,860,230
Bid: 0.060 Bid Size: 640,000
Ask: 0.067 Ask Size: 1,400,000
Day High: 0.062 Day Low: 0.052
52 Week High: 1.440 52 Week Low: 0.010
Market Cap: 3.13M Dividend: N/A
EPS: N/A P/E Ratio: N/A
6 Month Chart
CTIC - SharpCharts from StockCharts.com
3 Month Chart
CTIC - SharpCharts from StockCharts.com
CTIC - SharpCharts from StockCharts.com
RAiDAR alerts Learn More About RAiDAR-LT
02/20/2009 (16:05 ET) Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million - PR Newswire
02/18/2009 (01:30 ET) Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma - PR Newswire
02/17/2009 (20:30 ET) Cell Therapeutics to Resume Trading on MTA and NASDAQ - PR Newswire
02/17/2009 (17:30 ET) CTIC: Filed New Form 8-K, Material Event Disclosure - Edgar
02/17/2009 (17:30 ET) CTIC: Filed New Form S-3, Simplified Registration Statement - Edgar
02/11/2009 (18:01 ET) Cell Therapeutics Updates Shareholders on Trading - PR Newswire
02/10/2009 (16:16 ET) CTIC: Short Interest UP 77.6% to 329.5K at the End of Jan 2009 - Knobias
02/10/2009 (15:25 ET) CTIC: Filed New Form SC 13G/A, Beneficial Ownership Disclosure - Edgar
02/10/2009 (15:22 ET) CTIC: Filed New Form SC 13G/A, Beneficial Ownership Disclosure - Edgar
02/10/2009 (15:15 ET) CTIC: Filed New Form SC 13G/A, Beneficial Ownership Disclosure - Edgar
02/10/2009 (07:32 ET) CTIC: To Present At BIO CEO & Investor Conference @ 09:30 ET - Knobias
02/10/2009 (04:39 ET) Stockguru.com: Stocks to Watch for February 10, 2009 - CDCO, DCMT, SKVI, QNBC, and BCLI - M2 Communications
02/10/2009 (01:30 ET) Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone - PR Newswire
02/09/2009 (16:32 ET) CTIC: Filed New Form 8-K, Material Event Disclosure - Edgar
02/09/2009 (01:30 ET) Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast - PR Newswire
02/06/2009 (09:09 ET) Wall Street News Alert: Morning Watch: Stocks to Watch: CTIC, HDVY, ARTG - M2 Communications
02/06/2009 (07:40 ET) Cell Therapeutics Inc announces exchange of 83% of remaining convertible preferred stock - M2 Communications
02/06/2009 (01:30 ET) CTI Seeks Strategic Alternative for Italian Facility - PR Newswire
02/05/2009 (10:24 ET) BenchmarkJournal.com (Complimentary) Analyst Review for ILMN, ARTG, CTIC and OCNF - Market Wire
02/05/2009 (06:03 ET) CTIC: Filed New Form DEFR14A, Revised Definitive Proxy Statement - Edgar
02/05/2009 (01:30 ET) Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share - PR Newswire
02/04/2009 (07:53 ET) Market Research Reports, Research Reports, Company Profiles and Industry Analysis Cell Therapeutics, Inc.-Deals & Alliances Report - M2 Communications
02/02/2009 (13:31 ET) CTIC: Filed New Form 8-K, Material Event Disclosure - Edgar
01/29/2009 (20:18 ET) CTIC: New Form 4/A Filed, Change in Beneficial Ownership - Edgar
01/29/2009 (17:17 ET) CTIC: Filed New Form 8-K, Material Event Disclosure - Edgar
company profile
The Company focuses on the development, acquisition and commercialization of drugs for the treatment of cancer. ... MORE INFO
CONTACT: Dr. James A. Bianco, M.D. (CEO)
Cell Therapeutics Inc
501 Elliott Avenue West
Suite 400
Seattle, WA 98119
P: (206) 282-7100
P: (800) 215-CELL (US)
F: (206) 284-6206
Company Home Page | Email
Industry: Drugs
SIC: 2834
Employees: 230
Locations: 4
State of Inc: WASHINGTON 1991
Development Stage? N Transfer Agent:
Computershare Investor Services
Chicago, IL 60690
Investor Relations:
Company Authorized Shares: 200,000,000
Source: 10-Q ( 06/30/2008 )
Outstanding Shares: 58,464,608
Source: MGFS ( 11/06/2008 )
Fiscal Year End: December 31
MANAGEMENT & INSIDERS:
Need More Stock Research? Subscribe NOW!!!
Quotes and Research
3 Month Chart
CTIC - SharpCharts from StockCharts.com
ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.
Last edited by TGK; 02-21-2009 at 06:36 AM.
Reason: update
|
Checking For Related Data... |
View Profile
View Forum Posts
Private Message
Reply With Quote
Posting Permissions
Bookmarks